Synthesis of sulfonamide-conjugated glycosyl-amino acid building blocks

Marie Lopez, Laurent F. Bornaghi, Sally-Ann Poulsen*

Eskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland 4111, Australia.

*Corresponding author. Telephone: +61 7 3735 7825; e-mail: s.poulsen@griffith.edu.au

Abstract

The efficient synthesis of novel glycoconjugate amino acid building blocks wherein the amino acid and carbohydrate moieties are linked via a sulfonamide functional group is reported. The general reaction sequence consists of coupling a glycosyl thioacetate to an amino acid methyl ester followed by oxidation and deprotection of the carbohydrate moiety. We demonstrate the synthesis of derivatives from a range of amino acids, with reaction at either the α -amino group of amino acid precursors or the sidechain ϵ -amino group of lysine precursors.

Key Words

glycopeptide; isostere; peptidomimetic; deacetylation; carbohydrate; chemical biology

1. Introduction

The importance of carbohydrates and glycoconjugates in diverse biochemical processes has stimulated the development of neoglycoconjugates as fundamental tools for biological research.^{1,2} A central role for carbohydrate-protein conjugates in medicine is now well appreciated with glycoprotein based therapeutics representing more than one third of approved biopharmaceuticals, while glycopeptide antibiotics remain the frontline defence against a wide range of drug-resistant bacterial infections.³ Glycopeptides are formidable synthetic targets, with synthetic challenges far exceeding those associated with their oligopeptide counterparts. As well, native glycoproteins and glycopeptides comprise *O*-linked and *N*-linked glycosidic bonds and can lack the stability and bioavailability required in a therapeutic setting.² Glycopeptide mimetics may confer advantages over their native analogues, including stability towards degrading enzymes, improved bioavailability and reduced clearance rates. In addition, a non-native link between carbohydrate and amino acid moieties may provide added opportunities for interactions with the biological target leading to enhanced affinity and/or improved specificity. The development of glycoconjugate amino acid building blocks with non-native structural features thus opens new possibilities for the synthesis of biologically relevant glycopeptide mimetics.¹ Our group and others recently developed a synthesis for *S*-glycosyl sulfonamides and employed this new methodology to the synthesis of sulfonamide-bridged glycomimetics.⁴⁻⁶ In this contribution we further elaborate the scope of this chemistry to provide a simple, efficient and novel methodology for tethering sugar moieties to amino acids via a sulfonamide linker with potential for the application to a new class of glycopeptide mimetics.

2. Results and discussion

Our preliminary study was conducted using the simple amino acid glycine. The synthetic procedure towards carbohydrate-glycine glycoconjugates involved the reaction of *S*-acetyl thioglucose **1** with the α -amino group of glycine methyl ester to give the glycoconjugate sulfenamide **2a**, Scheme 1. Oxidation of **2a** provided the sulfonamide glycoconjugate **2b**, wherein the carbohydrate and glycine methyl ester are linked by a sulfonamide group. Standard Zemplén conditions⁷ for removal of the acetate protecting groups of the glycosyl moiety of **2b** (0.05 M NaOMe in MeOH, pH ~12) were employed to provide the deprotected glycoconjugate as the methyl ester **2c**, or alternatively using NaOH in place of NaOMe, to provide the deprotected

glycoconjugate as the free acid **2d**. All reactions proceeded in high yield and purifications were straightforward, Table 1, entries 1 and 2.

Scheme 1. Synthesis of glycoconjugate glycine building blocks with a sulfonamide linker.

Reagents and conditions. (i) a) 2.5 equiv. $\text{BrCH}(\text{CO}_2\text{Et})_2$, MeOH, rt, 20 min; b) 3.0 equiv. glycine methyl ester, 3.0 equiv DIPEA, rt, 2 h, 96%; (ii) 7.0 equiv. *m*CPBA, CH_2Cl_2 , rt, 1 h, 87%; (iii) NaOMe, MeOH, rt, 2 h, 94%; (iv) NaOH, MeOH, 0 °C to rt, 1 h; then Amberlite IR120- H^+ , quantitative.

We next extended this preliminary study to a selection of amino acid derivatives that encompassed variable side chain properties including aliphatic (valine), aromatic (phenylglycine), polar/alcohol (serine) and conformationally restricted (proline), Table 1. These amino acids were available enantiomerically pure as their methyl ester. The chemistry to form glycoconjugates proceeded as in Scheme 1, however the sugar acetate deprotection step (Scheme 1, step iii) for both the phenylglycine and serine glycoconjugates **4b** and **5b** gave **4c'** and **5c'** in high yield but as a mixture of two diastereomers, Table 1 entries 4 and 6. To avoid this racemization alternate non-basic acetate deprotection reaction conditions were sought. We investigated the removal of the acetate protecting groups of **4b** and **5b** under mild acidic conditions (8% HCl in methanol).⁸ The acetate groups were cleanly removed with retention of the amino acid α -carbon stereochemistry to give glycoconjugates **4c** (23%) and **5c** (36%) as a single diastereomer, Table 1 entries 5 and 7.

The biological activity of proteins and peptides may be enhanced by conjugation to carbohydrates.⁹ Synthetic strategies towards glycoconjugate amino acids may capitalize either on the inherent reactivity of the α -amino, carboxylic acid or side chain functionality of native amino acids or on introduced chemoselective reactivity of a modified side chain in a non-native amino acid.^{1,10-12} The glycoconjugate amino acids of our study were linked through reaction of the α -amino group of the amino acid so it is expected that conjugation of a sugar to the free *N*-terminus of a peptide or protein would be possible using this synthetic approach. In order to increase the generality of this method to allow site specific incorporation of a carbohydrate moiety into a peptide or protein it is necessary to apply this chemistry to the side chain of an amino acid. The sulfonamide linker has been previously employed as an amide bond isostere in the synthesis of peptidosulfonamide peptidomimetics.¹³ The ϵ -amino group of lysine is unique among native amino acids and lysine was selected as the candidate to evaluate side chain glycoconjugate formation through a sulfonamide linkage.

From L-lysine methyl ester dihydrochloride the disubstituted glycoconjugates **7a-c** were synthesized, Table 1, entry 9. Reaction occurred without difficulty (monitored by TLC) at the α -amino group while reaction of the sidechain ϵ -amino appeared relatively less favoured leading to a low yield of the disubstituted compound **7a** (30%). Similarly the reaction of *N*^{*α*}-acetyl-L-lysine methyl ester or *N*^{*α*}-fluorenylmethyloxycarbonyl-L-lysine with **1** also proceeded to form the sulfenamide-linked glycosyl amino acids **8a** (24%) and **9a** (14%) in low yields Table 2, entries 10 and 11. A reduced yield for the lysine sulfenamides **7a-9a** compared to sulfenamides **2a-6a** (yields >80%) identified a caveat to this methodology, which had so far proven high yielding. To avoid deacetylation of the sugar moiety of both reagent **1** and product sulfenamides it was necessary to maintain the pH value of the reaction (Scheme 1, step i) at ~pH 9. The pK_a value of the side chain of the ϵ -amino group of lysine is however ~10.5, rendering it predominantly protonated under the reaction conditions. A balance between maximising the conversion to sulfenamide product while avoiding deacetylation of the carbohydrate moieties resulted in overall reduced yields for reaction of the side chain lysine ϵ -amino group compared to the α -amino groups (pK_a values ~9-10). Despite this, the bis-sulfenamide **7a** was formed in 30% yield, while the yield for **8a** and **9a** was 24% and 14%, respectively, Table 1, entries 9-11. Given the ready

availability and low cost of starting reagents this limitation does not significantly impact quantities of target compounds that may be synthesized.

Table 1. Glycoconjugate amino acid building blocks synthesized from *S*-acetyl thioglucose **1** and various amino acids.

Entry	Amino acid	Product, Yield (%)	Product, Yield (%)	Product, Yield (%)
1		2a (96%)	2b (87%)	2c (94%)
2		2a (96%)	2b (87%)	2d (quantitative)
3		3a (90%)	3b (78%)	3c (93%)
4^a		4a (96%)	4b (87%)	4c' (99%)
5^b		4a (96%)	4b (87%)	4c (23%)
6^a		5a (81%)	5b (57%)	5c' (99%)
7^b		5a (81%)	5b (57%)	5c (36%)

^aDeprotection of per-*O*-acetylated glycoconjugates with basic conditions

^bDeprotection of per-*O*-acetylated glycoconjugates with acidic conditions

3. Experimental

3.1 General methods

All starting materials and reagents, including per-*O*-acetylated glucopyranose, were purchased from commercial suppliers. 1-*S*-Acetyl-2,3,4,6-tetra-*O*-acetyl-1-thio- β -D-glucopyranose (**1**) was synthesized as described earlier.¹⁴ All reactions were monitored by TLC. TLC plates were visualized with UV light, ninhydrin stain (1 g of ninhydrin in 100 mL of EtOH containing 3% (v/v) acetic acid) and/or orcinol stain (1 g of orcinol monohydrate in a mixture of EtOH:H₂O:H₂SO₄ 72.5:22.5:5 mL). Silica gel flash chromatography was performed using silica gel 60 Å (230-400 mesh). ¹H NMR were acquired at 500 MHz and ¹³C NMR at 125 MHz at 30 °C. For ¹H and ¹³C NMR acquired in CDCl₃ chemical shifts (δ) are reported in ppm relative to

the solvent residual peak: proton (δ 7.27 ppm) and carbon (δ 77.2 ppm). Chemical shifts for ^1H and ^{13}C NMR acquired in $\text{DMSO-}d_6$ are reported in ppm relative to residual solvent proton (δ 2.50 ppm) and carbon (δ 39.5 ppm) signals, respectively. Assignments for ^1H NMR were confirmed by ^1H - ^1H gCOSY, while assignments for ^{13}C NMR were confirmed by ^1H - ^{13}C HSQC. Multiplicity is indicated as follows: s (singlet); d (doublet); t (triplet); m (multiplet); dd (doublet of doublet); ddd (doublet of doublet of doublet); br (broad). Coupling constants are reported in Hertz (Hz). Melting points are uncorrected. High and low resolution electrospray ionization mass spectra were acquired using electrospray as the ionization technique in positive ion and/or negative ion modes as stated. All MS analysis samples were prepared as solutions in MeOH. Optical rotations were measured at 25 °C with Na-589 nm wave length and a 100 mm cell and reported as an average of ten measurements. Purity of all compounds was $\geq 95\%$ by NMR. Glycoconjugates are named in accordance with the recommendations of the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature: "Nomenclature of Carbohydrates (Recommendations 1996)" (<http://www.chem.qmul.ac.uk/iupac/2carb/>).

3.2 Synthesis methods

3.2.1 General procedure 1 – Synthesis of sulfenamide linked glycoconjugates

1-*S*-Acetyl-2,3,4,6-tetra-*O*-acetyl-1-thio- β -D-glucopyranose (**1**) (1 equiv.) was dissolved in anhydrous MeOH under nitrogen. Diethyl bromomalonate (2.5 equiv.) was added and the reaction stirred at rt under nitrogen for 20 min, then the amino acid methyl ester derivative (3.0 equiv.) and DIPEA (3.0 equiv.) added. The reaction was stirred at rt under nitrogen until complete as evidenced by TLC, typically 2 h. The MeOH was removed and the residue dissolved in CH_2Cl_2 and washed with brine ($\times 3$). Each aqueous fraction was back extracted with CH_2Cl_2 ($\times 2$). The combined organic fractions were dried over MgSO_4 , filtered and the solvent removed to give the product sulfenamides **2a-6a**, **8a-9a**.

3.2.2 General procedure 2 – Oxidation of sulfenamide linked glycoconjugates

The sulfenamide derivative (1.0 equiv.) was dissolved in CH_2Cl_2 . *meta*-Chloroperoxybenzoic acid (7.0 equiv.) in CH_2Cl_2 , was added dropwise over ~20 min. The reaction was maintained at rt until full disappearance of the starting material, as evidenced by TLC, typically 1 h. The reaction mixture was diluted in CH_2Cl_2 , quenched with $\text{NaHCO}_{3(\text{sat})}$, and filtered through celite. After

extraction with CH₂Cl₂, the organic fraction was washed with NaHCO₃(sat). (× 1) and brine (× 1). The aqueous fractions were back extracted with CH₂Cl₂ (× 2). The organic fractions were then combined, dried over MgSO₄, filtered and concentrated to give the expected sulfonamides **2b-9b**.

3.2.3 General procedure 3 - Deprotection of per-*O*-acetylated glycoconjugates with basic conditions

Fully deprotected glycoconjugates were prepared by treating a solution of the per-*O*-acetylated sulphonamide glycoconjugates **2b-7b** (1.0 equiv.) in anhydrous MeOH at 0 °C with methanolic sodium methoxide (0.05 M final concentration), pH 12. The reaction was warmed to rt and left to stir until full deprotection as evident by TLC (~1 h). The solution was neutralized with Amberlite IR-120 [H⁺], filtered and the resin washed several times with MeOH. The solvent was evaporated under reduced pressure, the residue redissolved in water and lyophilized to afford fully deprotected glycoconjugates **2c, 3c, 4c', 5c', 6c, 7c**.

3.2.4 General procedure 4 - Deprotection of per-*O*-acetylated glycoconjugates with acidic conditions

A solution of the per-*O*-acetylated glycoconjugate (**4b** or **5b**) was stirred overnight in 8% HCl in MeOH. The reaction mixture was concentrated in the presence of silica gel and the crude product purified by flash chromatography to afford the fully deprotected and stereochemically pure sulfonamide glycoconjugates **4c** or **5c**, respectively.

3.3 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl-β-D-glucosyl)thio]-glycinate (**2a**)

Glucoside **2a** was prepared from **1** and L-glycine methyl ester hydrochloride according to the general procedure 1. After purification by flash chromatography (1:2 EtOAc/hexane) the expected compound was obtained as an orange oil (96%): $[\alpha]_D^{25}$ -102 (*c* 1.0, CHCl₃); *R_f* 0.41 (2:3 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 5.33 (t, 1H, *J* 9.5 Hz, H-3), 5.08 (t, 1H, *J* 9.5 Hz, H-2), 4.86 (t, 1H, *J* 9.5 Hz, H-4), 4.62 (d, 1H, *J* 10.0 Hz, H-1), 4.09-4.01 (m, 3H, H-6a, H-6b, NH), 3.97 (ddd, 1H, *J* 2.5, 5.5, 7.0 Hz, H-5), 3.65 (d, 2H, *J* 6.5 Hz, NHCH₂), 3.64 (s, 3H, OCH₃), 2.02, 2.01, 1.99, 1.96 (4 × s, 12H, OCOCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.2 (CO₂CH₃), 170.0, 169.5, 169.4, 169.3 (4 × OCOCH₃), 87.4 (C-1), 74.3 (C-5), 73.1 (C-3), 68.1 (C-4), 67.3 (C-2), 62.1 (C-6), 54.6 (NHCH₂), 51.5 (CO₂CH₃), 20.5, 20.5, 20.3, 20.2 (4 ×

OCOCH₃); LRMS (ESI⁺): m/z 474 [M + Na]⁺; HRMS: Calcd for C₁₇H₂₅NO₁₁SNa [M + Na]⁺ 474.1041, Found 474.1053.

3.4 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl-β-*D*-glucosyl)thio]-*L*-valinate (**3a**)

Glucoside **3a** was prepared from **1** and *L*-valine methyl ester hydrochloride according to the general procedure 1. After purification by flash chromatography (1:2 EtOAc/hexane) the expected compound was obtained as a slightly yellow solid (90%): mp 90-93 °C; [α]_D²⁵ -138 (*c* 1.0, CHCl₃); R_f 0.41 (2:3 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 5.33 (t, 1H, *J* 9.5 Hz, H-3), 5.06 (t, 1H, *J* 9.5 Hz, H-2), 4.84 (t, 1H, *J* 9.5 Hz, H-4), 4.61 (d, 1H, *J* 10.5 Hz, H-1), 4.16 (dd, 1H, *J* 4.5, 12.0 Hz, H-6a), 3.99 (dd, 1H, *J* 2.5, 12.5 Hz, H-6b), 3.95 (m, 1H, H-5), 3.79 (d, 1H, *J* 9.5 Hz, NH), 3.64 (s, 3H, OCH₃), 3.28 (br d, 1H, *J* 9.5 Hz, NHCH), 2.00 (s, 6H, 2 × OCOCH₃), 1.98 (s, 3H, OCOCH₃), 1.95 (s, 3H, OCOCH₃), 1.93 (m, 1H, CH₃CHCH₃), 0.93 (d, 3H, *J* 7.0 Hz, CH₃CHCH₃), 0.88 (d, 3H, *J* 7.0 Hz, CH₃CHCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 174.4 (CO₂CH₃), 170.3, 169.9, 169.6, 169.5 (4 × OCOCH₃), 87.2 (C-1), 74.4 (C-5), 73.4 (C-3), 72.5 (NHCH), 68.0 (C-4), 67.3 (C-2), 61.9 (C-6), 51.8 (CO₂CH₃), 31.5 (CH₃CHCH₃), 20.7, 20.6, 20.5 (2C) (4 × OCOCH₃), 19.5, 18.2 (CH₃CHCH₃); LRMS (ESI⁺): m/z 494 [M + H]⁺, 516 [M + Na]⁺; HRMS: Calcd for C₂₀H₃₁NO₁₁SNa [M + Na]⁺ 516.1510, Found 516.1511.

3.5 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl-β-*D*-glucosyl)thio]-*R*-phenylglycinate (**4a**)

Glucoside **4a** was prepared from **1** and *R*-phenylglycine methyl ester hydrochloride according to the general procedure 1. After purification by flash chromatography (1:2 EtOAc/hexane) the expected compound was obtained as a yellow oil (96%): [α]_D²⁵ -135 (*c* 1.0, CHCl₃); R_f 0.58 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.36-7.29 (m, 5H, H_{arom.}), 5.35 (t, 1H, *J* 9.5 Hz, H-3), 5.13 (t, 1H, *J* 9.5 Hz, H-2), 4.90 (t, 1H, *J* 9.5 Hz, H-4), 4.73 (d, 1H, *J* 7.0 Hz, NHCH), 4.64 (d, 1H, *J* 7.0 Hz, NH), 4.62 (d, 1H, *J* 10.0 Hz, H-1), 4.09-4.05 (m, 2H, H-6a, H-6b), 3.98 (ddd, 1H, *J* 2.5, 5.5, 10.0 Hz, H-5), 3.63 (s, 3H, OCH₃), 2.03, 1.99, 1.98, 1.97 (4 × s, 12H, OCOCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.5 (CO₂CH₃), 170.0, 169.7, 169.5, 169.3 (4 × OCOCH₃), 138.0 (C_{arom.}), 129.4, 129.4, 128.0, 127.6, 127.6 (5 × CH_{arom.}), 87.3 (C-1), 74.4 (C-5), 72.9 (C-3), 68.7 (NHCH), 68.1 (C-4), 67.4 (C-2), 62.2 (C-6), 52.1 (CO₂CH₃), 20.7, 20.4, 20.3, 20.2 (4 × OCOCH₃); LRMS (ESI⁺): m/z 528 [M + H]⁺; HRMS: Calcd for C₂₃H₃₀NO₁₁SNa [M + Na]⁺ 528.1534, Found 528.1534.

3.6 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl- β -D-glucosyl)thio]-L-serinate (**5a**)

Glucoside **5a** was prepared from **1** and L-serine methyl ester hydrochloride according to the general procedure 1. After purification by flash chromatography (3:2 EtOAc/hexane) the expected compound was obtained as an orange oil (81%): $[\alpha]_{\text{D}}^{25}$ -143 (*c* 1.0, CHCl₃); R_f 0.22 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 5.33 (t, 1H, *J* 9.5 Hz, H-3), 5.01 (t, 1H, *J* 9.5 Hz, H-2), 4.90 (t, 1H, *J* 5.0 Hz, CH₂OH), 4.89 (t, 1H, *J* 9.5 Hz, H-4), 4.60 (d, 1H, *J* 9.5 Hz, H-1), 4.10 (dd, 1H, *J* 4.5, 12.5 Hz, H-6a), 4.05 (dd, 1H, *J* 2.5, 12.5 Hz, H-6b), 3.96 (ddd, 1H, *J* 2.5, 4.5, 10.0 Hz, H-5), 3.86 (d, 1H, *J* 8.0 Hz, NH), 3.66 (dd, 2H, *J* 5.0, 10.0 Hz, CH₂OH), 3.64 (s, 3H, CO₂CH₃), 3.55 (m, 1H, NHCH), 2.01 (s, 6H, 2 $\times$ OCOCH₃), 1.98 (s, 3H, OCOCH₃), 1.95 (s, 3H, OCOCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.5 (CO₂CH₃), 170.0, 169.5, 169.3, 169.2 (4 $\times$ OCOCH₃), 87.1 (C-1), 74.1 (C-5), 73.0 (C-3), 67.9 (C-4), 67.8 (NHCH), 67.3 (C-2), 62.3 (CH₂OH), 61.8 (C-6), 51.6 (CO₂CH₃), 20.5, 20.4, 20.3, 20.2 (4 $\times$ OCOCH₃); LRMS (ESI⁺): *m/z* 482 [M + H]⁺, 504 [M + Na]⁺; HRMS: Calcd for C₁₈H₂₈N₁O₁₂S 482.1327, Found 482.1303.

3.7 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl- β -D-glucosyl)thio]-L-prolinate (**6a**)

Glucoside **6a** was prepared from **1** and L-proline methyl ester hydrochloride according to the general procedure 1. After purification by flash chromatography (2:3 EtOAc/hexane) expected compound was obtained as an off white solid (98%): mp 89-90 °C; $[\alpha]_{\text{D}}^{25}$ -101 (*c* 1.0, CHCl₃); R_f 0.53 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 5.31 (t, 1H, *J* 9.5 Hz, H-3), 5.01 (d, 1H, *J* 10.5 Hz, H-1), 4.88 (t, 1H, *J* 9.5 Hz, H-4), 4.77 (t, 1H, *J* 9.5 Hz, H-2), 4.12 (dd, 1H, *J* 5.0, 12.5 Hz, H-6a), 4.02 (dd, 1H, *J* 2.5, 13.0 Hz, H-6b), 3.99 (m, 1H, H-5), 3.84 (dd, 1H, *J* 4.0, 9.0 Hz, α -CH), 3.63 (s, 3H, OCH₃), 3.19 (m, 2H, δ -CH₂), 2.19 (m, 1H, β -CHH), 1.82-1.78 (m, 3H, β -CHH, δ -CH₂), 2.01, 1.99, 1.98, 1.94 (4 $\times$ s, 12H, OCOCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.5 (CO₂CH₃), 170.0, 169.5, 169.3, 169.2 (4 $\times$ OCOCH₃), 85.8 (C-1), 74.2 (C-5), 73.1 (C-3), 68.0 (C-4), 67.8 (C-2), 66.9 (α -CH), 62.0 (C-6), 56.6 (δ -CH₂), 51.6 (CO₂CH₃), 30.4 (β -CH₂), 24.4 (γ -CH₂), 20.4, 20.3, 20.3, 20.2 (4 $\times$ OCOCH₃); LRMS (ESI⁺): *m/z* 492 [M + H]⁺, 514 [M + Na]⁺; HRMS: Calcd for C₂₀H₂₉NO₁₁SNa [M + Na]⁺ 514.1354, Found 514.1336.

3.8 Methyl *N,N*-[di-[(2,3,4,6-tetra-*O*-acetyl- β -D-glucosyl)thio]]-L-lysinate (**7a**)

A solution of compound **1** (347 mg, 0.85 mmol, 1.0 equiv.) in anhydrous MeOH (10 mL) was stirred for 30 min under argon in presence of diethyl bromomalonate (0.37 mL, 2.17 mmol, 2.6 equiv.). A solution of L-lysine methyl ester hydrochloride (605 mg, 2.60 mmol, 3.1 equiv.) in anhydrous MeOH (20 mL) and DIPEA (0.9 mL, 5.17 mmol, 6.0 equiv.) were added and the mixture was stirred under argon at rt for 2 h. The solvent was evaporated and the residue was dissolved in CH₂Cl₂ and washed with brine (× 2). After back extraction of each aqueous fraction with CH₂Cl₂ (× 2) the organic fractions were combined, dried over MgSO₄, filtered and concentrated to afford a monosubstituted derivative used for the next step as a crude mixture. The same procedure as above was repeated to afford the second substitution. Purification by flash chromatography (1:1 EtOAc/hexane) afforded the title compound **7a** as a yellow oil (30%): $[\alpha]_D^{25} +106$ (*c* 1.0, CHCl₃); *R_f* 0.64 (2:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 5.32 (2 × t, 2H, *J* 9.0 Hz, H-3, H-3'), 4.96 (t, 1H, *J* 9.5 Hz, H-2 or H-2'), 4.90-4.83 (m, 3H, H-2 or H-2', H-4, H-4'), 4.69, 4.63 (2 × d, 2H, *J* 10.0 Hz, H-1, H-1'), 4.14-4.10 (m, 2H, H-6a, H-6a'), 4.05-4.02 (m, 2H, NH, H-6b or H-6b'), 4.00 (dd, 1H, *J* 12.5, 2.0 Hz, H-6b or H-6b'), 3.95 (2 × ddd, 2H, *J* 10.0, 4.5, 2.0 Hz, H-5, H-5'), 3.74 (t, 1H, *J* 5.5 Hz, ε-NH), 3.63 (s, 3H, OCH₃), 3.45 (td, 1H, *J* 8.0, 6.0 Hz, α-CH), 2.82 (m, 2H, ε-CH₂), 2.02 (s, 3H, OCOCH₃), 2.01 (s, 6H, 2 × OCOCH₃), 2.00 (s, 3H, OCOCH₃), 1.98 (s, 6H, 2 × OCOCH₃), 1.94 (s, 6H, 2 × OCOCH₃), 1.58 (m, 2H, β-CH₂), 1.42 (m, 2H, δ-CH₂), 1.34 (m, 2H, γ-CH₂); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 174.3 (CO₂CH₃), 169.9, 169.9, 169.5, 169.2, 169.2, 169.2, 169.1, 168.4 (8 × OCOCH₃), 87.6, 87.4 (C-1, C-1'), 74.2, 74.2 (C-5, C-5'), 73.2, 73.2 (C-3, C-3'), 68.1, 68.0 (C-4, C-4'), 67.6, 67.4 (C-2, C-2'), 65.5 (α-CH), 61.9, 61.9 (C-6, C-6'), 52.6 (ε-CH₂), 51.6 (CO₂CH₃), 32.2 (β-CH₂), 29.3 (δ-CH₂), 22.5 (γ-CH₂), 20.4, 20.4, 20.3(×6) (8 × OCOCH₃); LRMS (ESI⁺): *m/z* 885 [M + H]⁺; HRMS: Calcd for C₃₅H₅₃N₂O₂₀S₂ 885.2628, Found 885.2669.

3.9 *N*^α-Fluorenylmethyloxycarbonyl-*N*^ε-[(2,3,4,6-tetra-*O*-acetyl-β-D-glucosyl)thio]-L-lysine (**8a**)

The title compound **8a** was prepared from *N*^α-fluorenylmethyloxycarbonyl-L-lysine according to the general procedure 1. Purification by flash chromatography (4:1 EtOAc/petroleum spirit + AcOH 1.5% v/v) afforded the title compound **8a** as a colorless oil (14%): $[\alpha]_D^{25} -94$ (*c* 1.0, CHCl₃); *R_f* 0.24 (4:1 EtOAc/hexane + 1.5% acetic acid); ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.89

(d, 2H, J 7.5 Hz, $H_{\text{arom.}}$), 7.72 (d, 2H, J 7.5 Hz, $H_{\text{arom.}}$), 7.42 (t, 2H, J 7.5 Hz, $H_{\text{arom.}}$), 7.33 (t, 2H, J 7.5 Hz, $H_{\text{arom.}}$), 5.34 (t, 1H, J 9.5 Hz, H-3), 5.17 (d, 1H, J 10.5 Hz, H-1), 4.91 (t, 1H, J 9.5 Hz, H-4), 4.68 (t, 1H, J 10.0 Hz, H-2), 4.28-4.19 (m, 2H, H-6a, H-6b), 4.12 (m, 1H, H-5), 4.04 (m, 1H, NH_{Fmoc}), 3.87 (m, 1H, SNH); 3.30 (m, 3H, $\text{CH}_{2\text{Fmoc}}$, CH_{Fmoc}), 2.00, 1.99, 1.98, 1.94 ($4 \times$ s, 12H, OCOCH_3), 1.72 (m, 2H, $\epsilon\text{-CH}_2$), 1.59 (m, 2H, $\delta\text{-CH}_2$), 1.28 (m, 3H, $\alpha\text{-CH}$, $\beta\text{-CH}_2$), 0.85 (m, 2H, $\gamma\text{-CH}_2$); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 172.5 (CO_2H), 172.5 (OCONH), 170.5, 170.0, 169.7, 169.5 ($4 \times \text{OCOCH}_3$), 143.0, 139.9, 137.9, 135.8, 129.9, 129.4, 129.4, 127.7, 127.7, 121.8, 121.8, 120.5, 120.5 ($13 \times \text{C}_{\text{Fmoc}}$); 110.2 (C-1), 74.7 (C-5), 73.5 (C-3); 68.4 (C-2 or C-4); 68.2 (C-2 or C-4); 62.4 (C-6), 54.6 ($\alpha\text{-CH}$); 52.1 ($\text{CH}_{2\text{Fmoc}}$); 40.4, 21.1, 21.1, 21.1 ($4 \times \text{CH}_2$); 20.9, 20.8, 20.8, 20.7 ($4 \times \text{OCOCH}_3$); LRMS (ESI^+): m/z 731 [$\text{M} + \text{H}$] $^+$.

3.10 Methyl N^α -acetyl- N^ϵ -[(2,3,4,6-tetra- O -acetyl- β -D-glucosyl)thio]-L-lysinate (**9a**)

The title compound **9a** was prepared from N^α -acetyl-L-lysine methyl ester according to the general procedure 1, using 1.0 equiv. of lysine derivative and 2.3 equiv. of DIPEA. A purification by flash chromatography (4:1 EtOAc/hexane) afforded the title compound **9a** as a colorless oil (24%): R_f 0.28 (4:1 EtOAc/hexane); ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 8.18 (d, 1H, J 7.5 Hz, NHAc), 5.32 (t, 1H, J 9.5 Hz, H-3), 4.87 (t, 1H, J 9.5 Hz, H-4), 4.86 (t, 1H, J 9.5 Hz, H-2), 4.68 (d, 1H, J 10.0 Hz, H-1), 4.18 (td, 1H, J 8.0, 5.0 Hz, $\alpha\text{-CH}$), 4.12 (dd, 1H, J 12.5, 5.0 Hz, H-6a), 4.04 (dd, 1H, J 12.5, 2.0 Hz, H-6b), 3.98 (ddd, 1H, J 10.0, 5.0, 2.5 Hz, H-5), 3.75 (t, 1H, J 5.5 Hz, SNH), 3.61 (s, 3H, OCH_3), 2.79 (m, 2H, $\epsilon\text{-CH}_2$), 2.01, 2.00, 1.99, 1.94 ($4 \times$ s, 12H, OCOCH_3), 1.84 (s, 3H, NHCOCH_3), 1.60 (m, 2H, $\beta\text{-CH}_2$), 1.40 (m, 2H, $\delta\text{-CH}_2$), 1.26 (m, 2H, $\gamma\text{-CH}_2$); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 172.8 (CO_2CH_3), 170.0, 169.5, 169.4, 169.3, 169.3 (NHCOCH_3 , $4 \times \text{OCOCH}_3$), 87.5 (C-1), 74.2 (C-5), 73.3 (C-3), 68.1 (C-4), 67.6 (C-2), 62.0 (C-6), 52.6 ($\epsilon\text{-CH}_2$), 51.9 ($\alpha\text{-CH}$), 51.7 (CO_2CH_3), 30.8 ($\beta\text{-CH}_2$), 29.2 ($\delta\text{-CH}_2$), 22.6 ($\gamma\text{-CH}_2$), 22.2, 20.5, 20.5, 20.3, 20.3 (NHCOCH_3 , $4 \times \text{OCOCH}_3$); LRMS (ESI^+): m/z 565 [$\text{M} + \text{H}$] $^+$, 587 [$\text{M} + \text{Na}$] $^+$. HRMS: Calcd for $\text{C}_{23}\text{H}_{36}\text{N}_2\text{O}_{12}\text{SNa}$ [$\text{M} + \text{Na}$] $^+$ 565.2062, Found 565.2084.

3.11 Methyl N -[(2,3,4,6-tetra- O -acetyl- β -D-glucosyl)sulfonyl]-glycinate (**2b**)

Derivative **2b** was prepared by oxidation of compound **2a** according to the general procedure 2. After purification by flash chromatography (3:2 EtOAc/hexane) expected compound **2b** was

obtained as a white solid (87%): mp 123-124 °C; $[\alpha]_{\text{D}}^{25}$ -25 (*c* 1.0, CHCl₃); *R_f* 0.22 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.02 (br s, 1H, NH), 5.39 (t, 1H, *J* 9.5 Hz, H-3), 5.28 (t, 1H, *J* 9.5 Hz, H-2), 4.93 (d, 1H, *J* 9.5 Hz, H-1), 4.91 (t, 1H, *J* 9.5 Hz, H-4), 4.15-4.10 (m, 2H, H-5, H-6a), 4.04 (m, 1H, H-6b), 3.83 (br d, 1H, *J* 4.0 Hz, NHCH₂), 3.67 (s, 3H, OCH₃), 2.02, 1.99, 1.96, 1.95 (4 × s, 12H, OCOCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 170.0 (CO₂CH₃), 169.9, 169.5, 169.2, 168.7 (4 × OCOCH₃), 86.8 (C-1), 74.4 (C-5), 72.6 (C-3), 67.5 (C-4), 67.4 (C-2), 61.6 (C-6), 51.9 (CO₂CH₃), 44.3 (NHCH₂), 20.4, 20.4, 20.3, 20.2 (4 × OCOCH₃); LRMS (ESI⁺): *m/z* 501 [M + NH₄]⁺, 506 [M + Na]⁺; HRMS: Calcd for C₁₇H₂₅NO₁₃SNa [M + Na]⁺ 506.0939, Found 506.0929.

3.12 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl-β-*D*-glucosyl)sulfonyl]-*L*-valinate (**3b**)

Glycoconjugate **3b** was prepared by oxidation of compound **3a** according to the general procedure 2. After purification by flash chromatography (2:3 then 1:1 EtOAc/hexane) expected compound **3b** was obtained as a white solid (78%): mp 104-105 °C; $[\alpha]_{\text{D}}^{25}$ -30 (*c* 1.0, CHCl₃); *R_f* = 0.37 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.25 (d, 1H, *J* 8.5 Hz, NH), 5.41 (t, 1H, *J* 9.5 Hz, H-3), 5.17 (t, 1H, *J* 9.5 Hz, H-2), 4.94 (d, 1H, *J* 9.5 Hz, H-1), 4.91 (t, 1H, *J* 9.5 Hz, H-4), 4.20 (dd, 1H, *J* 4.5, 12.5 Hz, H-6a), 4.09 (ddd, 1H, *J* 2.5, 4.5, 10.0 Hz, H-5), 3.91 (dd, 1H, *J* 2.5, 12.5 Hz, H-6b), 3.25 (dd, 1H, *J* 6.5, 8.5 Hz, NHCH), 3.66 (s, 3H, OCH₃), 2.01 (s, 3H, OCOCH₃), 1.99 (m, 1H, CH₃CHCH₃), 1.98, 1.95, 1.94 (3 × s, 9H, OCOCH₃), 0.89 (d, 3H, *J* 7.0 Hz, CH₃CHCH₃); 0.88 (d, 3H, *J* 7.0 Hz, CH₃CHCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 171.7 (CO₂CH₃), 170.0, 169.5, 169.1, 168.6 (4 × OCOCH₃), 85.6 (C-1), 74.4 (C-5), 72.6 (C-3), 67.4 (C-4), 67.3 (C-2), 61.8 (NHCH), 61.4 (C-6), 51.8 (CO₂CH₃), 30.5 (CH₃CHCH₃), 20.4, 20.4, 20.3, 20.2 (4 × OCOCH₃), 18.8, 17.9 (CH₃CHCH₃); LRMS (ESI⁺): *m/z* 543 [M + NH₄]⁺, 548 [M + Na]⁺; HRMS: Calcd for C₂₀H₃₁N₁O₁₃SNa [M + Na]⁺ 548.1408, Found 548.1407.

3.13 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl-β-*D*-glucosyl)sulfonyl]-*R*-phenylglycinate (**4b**)

Glycoconjugate **4b** was prepared by oxidation of compound **4a** according to the general procedure 2. After purification by flash chromatography (3:2 EtOAc/hexane) expected compound **4b** was obtained as a white solid (87%): mp 204-205 °C; $[\alpha]_{\text{D}}^{25}$ -100 (*c* 1.0, CHCl₃); *R_f* 0.37 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.88 (d, 1H, *J* 9.0 Hz, NH), 7.42-7.34 (m, 5H, H_{arom.}), 5.38 (t, 1H, *J* 9.5 Hz, H-3), 5.22 (t, 1H, *J* 9.5 Hz, H-2), 5.12 (d, 1H, *J*

9.0 Hz, NHCH), 4.97 (d, 1H, *J* 9.5 Hz, H-1), 4.83 (t, 1H, *J* 9.5 Hz, H-4), 4.15-4.10 (m, 2H, H-5, H-6a), 3.85 (m, 1H, H-6b), 3.68 (s, 3H, OCH₃), 2.00, 1.98, 1.95, 1.93 (4 × s, 12H, OCOCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 70.8 (CO₂CH₃), 170.0, 169.5, 169.2, 168.7 (4 × OCOCH₃), 136.3 (C_{arom.}), 128.5, 128.5, 128.3, 127.4, 127.4 (5 × CH_{arom.}), 86.8 (C-1), 74.5 (C-5), 72.6 (C-3), 67.6 (C-2), 67.4 (C-4), 61.5 (C-6), 59.9 (NHCH), 52.5 (CO₂CH₃), 20.4, 20.4, 20.3, 20.2 (4 × OCOCH₃); LRMS (ESI⁺): *m/z* 577 [M + NH₄]⁺, 582 [M + Na]⁺; HRMS: Calcd for C₂₃H₂₉NO₁₃SNa [M + Na]⁺ 582.1252, Found 582.1274.

3.14 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl-β-D-glucosyl)sulfonyl]-L-serinate (**5b**)

Glycoconjugate **5b** was prepared by oxidation of compound **5a** according to the general procedure 2. After purification by flash chromatography (3:2 EtOAc/hexane) expected compound **5b** was obtained as a white solid (57%): mp 179-180 °C; [α]_D²⁵ -40 (*c* 1.0, CHCl₃); R_f 0.22 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.92 (br s, 1H, NH), 5.37 (t, 1H, *J* 9.5 Hz, H-3), 5.20 (t, 1H, *J* 9.5 Hz, H-2), 5.06 (br t, 1H, *J* 5.5 Hz, NHCH), 4.94 (d, 1H, *J* 10.0 Hz, H-1), 4.93 (t, 1H, *J* 10.5 Hz, H-4), 4.18 (dd, 1H, *J* 4.5, 12.5 Hz, H-6a), 4.11 (m, 1H, H-5), 4.01 (t, 1H, *J* 5.0 Hz, CH₂OH), 3.97 (dd, 1H, *J* 1.5, 12.5 Hz, H-6b), 3.67 (m, 2H, CH₂OH), 3.66 (s, 3H, OCH₃), 2.01, 1.98, 1.95, 1.94 (4 × s, 12H, OCOCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 170.7 (CO₂CH₃), 170.1, 169.6, 169.3, 168.9 (4 × OCOCH₃), 86.2 (C-1), 74.5 (C-5), 72.8 (C-3), 67.5 (C-4), 67.4 (C-2), 62.6 (NHCH), 61.4 (C-6), 58.5 (CH₂OH), 52.1 (CO₂CH₃), 20.5, 20.5, 20.4, 20.3 (4 × OCOCH₃); LRMS (ESI⁺): *m/z* 531 [M + NH₄]⁺, 536 [M + Na]⁺; HRMS: Calcd for C₁₈H₂₇NO₁₄SNa [M + Na]⁺ 536.1044, Found 536.1054.

3.15 Methyl *N*-[(2,3,4,6-tetra-*O*-acetyl-β-D-glucosyl)sulfonyl]-L-prolinate (**6b**)

Glycoconjugate **6b** was prepared by oxidation of compound **6a** according to the general procedure 2. After purification by flash chromatography (1:1 EtOAc/hexane) expected compound **6b** was obtained as a white solid (64%): mp 181-182 °C; [α]_D²⁵ -58 (*c* 1.0, CHCl₃); R_f 0.32 (1:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 5.31 (d, 1H, *J* 9.0 Hz, H-1), 5.29 (t, 1H, *J* 9.5 Hz, H-3), 5.26 (t, 1H, *J* 9.0 Hz, H-2), 4.94 (t, 1H, *J* 9.5 Hz, H-4), 4.41 (dd, 1H, *J* 4.0, 8.5 Hz, α-CH), 4.16-4.09 (m, 3H, H-5, H-6a, H-6b), 3.66 (s, 3H, OCH₃), 3.65 (m, 1H, δ-CHH), 3.41 (m, 1H, δ-CHH); 2.28 (m, 1H, β-CHH), 2.02 (s, 6H, 2 × OCOCH₃), 2.00 (s, 3H, OCOCH₃),

1.95 (s, 3H, OCOCH₃), 1.92-1.87 (m, 3H, γ -CH₂, β -CHH); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.2 (CO₂CH₃), 169.9, 169.5, 169.2, 168.5 (4 $\times$ OCOCH₃), 85.9 (C-1), 74.8 (C-5), 72.7 (C-3), 67.4 (C-4), 67.1 (C-2), 61.8 (C-6), 59.8 (α -CH), 52.1 (CO₂CH₃), 50.1 (δ -CH₂), 30.9 (β -CH₂), 24.3 (γ -CH₂), 20.4, 20.3, 20.3, 20.2 (4 $\times$ OCOCH₃); LRMS (ESI⁺): *m/z* 541 [M + NH₄]⁺, 546 [M + Na]⁺; HRMS: Calcd for C₂₀H₂₉NO₁₃SNa [M + Na]⁺ 546.1252, Found 546.1234.

3.16 Methyl *N,N*-[di-[(2,3,4,6-tetra-*O*-acetyl- β -D-glucosyl)sulfonyl]]-L-lysinate (7b)

The title compound **7b** was obtained from compound **7a** according to the general procedure 3. A purification by flash chromatography (2:1 EtOAc/hexane) afforded the title compound **7b** as a white solid (39%): mp 78-80 °C; [α]_D²⁵ -31 (*c* 1.0, CHCl₃); R_f 0.24 (2:1 EtOAc/hexane); ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.29 (d, 1H, *J* 8.0 Hz, α -NH), 7.56 (t, 1H, *J* 6.0 Hz, ϵ -NH), 5.39 (t, 1H, *J* 9.5 Hz, H-3 or H-3'), 5.38 (t, 1H, *J* 9.5 Hz, H-3 or H-3'), 5.18 (t, 1H, *J* 9.5 Hz, H-2 or H-2'), 5.17 (t, 1H, *J* 9.5 Hz, H-2 or H-2'), 4.93-4.89 (m, 4H, H-1, H-1', H-4, H-4'), 4.22 (dd, 1H, *J* 13.0, 5.0 Hz, H-6a or H-6a'), 4.20-4.15 (m, 2H, H-5 or H-5', H-6a or H-6a'), 4.11 (ddd, 1H, *J* 10.0, 4.5, 2.0 Hz, H-5 or H-5'), 4.03 (br d, 1H, *J* 10.5 Hz, H-6b or H6b'), 3.92 (dd, 1H, *J* 12.5, 2.0 Hz, H-6b or H6b'), 3.88 (m, 1H, α -CH), 3.66 (s, 3H, OCH₃), 2.98 (m, 2H, ϵ -CH₂), 2.01 (s, 3H, OCOCH₃), 1.99 (s, 6H, 2 $\times$ OCOCH₃), 1.98 (s, 3H, OCOCH₃), 1.95 (s, 6H, 2 $\times$ OCOCH₃), 1.94 (s, 6H, 2 $\times$ OCOCH₃), 1.63 (m, 2H, β -CH₂), 1.45 (m, 2H, δ -CH₂), 1.34 (m, 2H, γ -CH₂); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.1 (CO₂CH₃), 170.0, 169.9, 169.5, 169.5, 169.2, 169.1, 168.6, 168.5 (8 $\times$ OCOCH₃), 85.9, 85.5 (C-1, C-1'), 74.4, 74.3 (C-5, C5'), 72.8, 72.7 (C-3, C-3'), 67.6, 67.6 (C-4, C-4'), 67.4, 67.3 (C-2, C-2'), 61.7, 61.4 (C-6, C-6'), 56.0 (α -CH), 52.0 (OCH₃), 42.7 (ϵ -CH₂), 31.8 (β -CH₂), 29.3 (δ -CH₂), 22.1 (γ -CH₂), 20.4 ($\times$ 4), 20.3, 20.3, 20.2, 20.2 (8 $\times$ OCOCH₃); LRMS (ESI⁺): *m/z* 971 [M + Na]⁺; HRMS: Calcd for C₃₅H₅₂N₂O₂₄S₂Na [M + Na]⁺ 971.2244, Found 971.2260.

3.17 *N* ^{α} -Fluorenylmethyloxycarbonyl-*N* ^{ϵ} -[(2,3,4,6-tetra-*O*-acetyl- β -D-glucosyl)sulfonyl]-L-lysine (8b)

The title compound **8b** was prepared from compound **8a** according to the general procedure 3. Purification by flash chromatography (3:2 acetone/hexane + AcOH 1.4% v/v) afforded the title compound **8b** as a yellow oil (69%): [α]_D²⁵ -25 (*c* 1.0, CHCl₃); R_f 0.33 (3:2 acetone/hexane +

AcOH 1.4% v/v); ^1H NMR (500 MHz, DMSO- d_6): δ 7.89 (d, 2H, J 7.5 Hz, $\text{H}_{\text{arom.}}$), 7.72 (m, 2H, $\text{H}_{\text{arom.}}$), 7.45 (m, 1H, SO_2NH), 7.42 (t, 2H, J 7.5 Hz, $\text{H}_{\text{arom.}}$), 7.33 (q, 2H, J 7.5 Hz, $\text{H}_{\text{arom.}}$), 3.30 (s, 1H, CH_{Fmoc}), 5.40 (t, 1H, J 9.0 Hz, H-3), 5.05 (d, 1H, J 10.0 Hz, H-2), 4.96 (t, 1H, J 9.5 Hz, H-4), 4.73 (d, 1H, J 10.0 Hz, H-1), 4.29-4.13 (m, 3H, H-5, H-6a, H-6b), 3.92 (m, 2H, $\epsilon\text{-CH}_2$), 3.42 (br s, 2H, CH_2Fmoc), 3.18 (m, 1H, FmocNH), 2.02, 1.99, 1.97, 1.94 ($4 \times$ s, 12H, OCOCH_3), 1.75 (m, 1H, $\alpha\text{-CH}$), 1.64 (m, 2H, $\delta\text{-CH}_2$), 1.28 (m, 2H, $\beta\text{-CH}_2$), 0.84 (m, 2H, $\gamma\text{-CH}_2$); ^{13}C NMR (125 MHz, DMSO- d_6): δ 172.0 (CO_2H), 170.2, 169.6, 169.5, 169.2 ($4 \times$ OCOCH_3), 142.6, 139.4, 137.4, 128.9, 128.9, 127.3, 127.3, 121.3, 121.3, 120.0 ($\times 3$), 109.7 ($13 \times \text{C}_{\text{Fmoc}}$), 90.3 (C-1), 74.4 (C-5), 72.5 (C-3), 68.4 (C-2 or C-4), 68.2 (C-2 or C-4), 61.4 (C-6), 55.8 ($\alpha\text{-CH}$), 45.6 (CH_2Fmoc), 30.6, 29.5, 21.1, 21.1 ($4 \times \text{CH}_2$), 20.5, 20.3, 20.3, 20.2 ($4 \times \text{OCOCH}_3$); LRMS (ESI^+): m/z 785 [$\text{M} + \text{Na}$] $^+$; (ESI^-): m/z = 761 [$\text{M} - \text{H}$] $^-$; HRMS: Calcd for $\text{C}_{35}\text{H}_{42}\text{N}_2\text{O}_{15}\text{SNa}$ [$\text{M} + \text{Na}$] $^+$ 785.2198, Found 785.2232.

3.18 Methyl N^a -acetyl- N^c -[(2,3,4,6-tetra- O -acetyl- β -D-glucosyl)sulfonyl]-L-lysinate (**9b**)

The title compound **9b** was obtained from compound **9a** according to the general procedure 3. Purification by flash chromatography (3:2 acetone/hexane) afforded the title compound **9b** as a colorless oil (33%): R_f 0.27 (3:2 acetone/hexane); ^1H NMR (500 MHz, DMSO- d_6): δ 8.33 (d, 1H, J 7.0 Hz, NHAc), 7.80 (t, 1H, J 5.5 Hz, $\epsilon\text{-NH}$), 5.40 (t, 1H, J 8.0 Hz, H-3), 5.17 (t, 1H, J 8.0 Hz, H-2), 4.93 (d, 1H, J 8.5 Hz, H-1), 4.92 (t, 1H, J 8.5 Hz, H-4), 4.22 (dd, 1H, J 10.5, 4.0 Hz, H-6a), 4.12 (ddd, 1H, J 8.5, 4.0, 2.0 Hz, H-5), 3.91 (dd, 1H, J 10.5, 2.0 Hz, H-6b), 3.86 (td, 1H, J 7.5, 4.5 Hz, $\alpha\text{-CH}$), 3.65 (s, 3H, OCH_3), 2.99 (m, 2H, $\epsilon\text{-CH}_2$), 2.01, 1.98, 1.95, 1.94 ($4 \times$ s, 12H, OCOCH_3), 1.78 (s, 3H, NHCOCH_3), 1.61 (m, 2H, $\beta\text{-CH}_2$), 1.38 (m, 2H, $\delta\text{-CH}_2$), 1.31 (m, 2H, $\gamma\text{-CH}_2$); ^{13}C NMR (125 MHz, DMSO- d_6): δ 172.4 (CO_2CH_3), 170.3, 169.8, 169.6, 169.5, 168.9 ($4 \times \text{OCOCH}_3$, NHCOCH_3), 86.0 (C-1), 74.6 (C-5), 72.9 (C-3), 67.6 (C-2 or C-4), 67.5 (C-2 or C-4), 61.6 (C-6), 56.3 ($\alpha\text{-CH}$), 38.5 ($\epsilon\text{-CH}_2$), 32.5, 28.6, 24.0 ($3 \times \text{CH}_2$), 22.7 (OCH_3); 20.6, 20.6, 20.5, 20.4, 20.0 ($4 \times \text{OCOCH}_3$, NHCOCH_3); LRMS (ESI^+): m/z 598 [$\text{M} + \text{H}$] $^+$, 619 [$\text{M} + \text{Na}$] $^+$; HRMS: Calcd for $\text{C}_{23}\text{H}_{36}\text{N}_2\text{O}_{14}\text{SNa}$ [$\text{M} + \text{Na}$] $^+$ 619.1779, Found 619.1790.

3.19 Methyl N -[(β -D-glucosyl)sulfonyl]-glycinate (**2c**)

The title compound **2c** was obtained from the per-acetylated derivative **2b** following the general procedure 3. Lyophilization afforded the title compound **2c** as a hygroscopic slightly yellow solid (94%): $[\alpha]_D^{25}$ -11 (*c* 1.0, MeOH); R_f 0.43 (95:5 CH₃CN/H₂O); ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.49 (br s, 1H, NH), 5.13 (m, 2H, OH-2, OH-3), 5.03 (d, 1H, *J* 4.5 Hz, OH-4), 4.47 (br s, 1H, OH-6), 4.22 (d, 1H, *J* 9.5 Hz, H-1), 3.85 (m, 2H, NHCH₂), 3.67 (dd, 1H, *J* 4.5, 11.5 Hz, H-6a), 3.65 (s, 3H, OCH₃), 3.44 (m, 2H, H-2, H-6b), 3.22 (m, 2H, H-3, H-5), 3.05 (m, 1H, H-4); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 170.1 (CO₂CH₃), 90.5 (C-1), 81.2 (C-5), 77.4 (C-3), 70.4 (C-4), 69.5 (C-2), 61.0 (C-6), 51.8 (OCH₃), 51.8 (NHCH₂); LRMS (ESI⁺): *m/z* 338 [M + Na]⁺; HRMS: Calcd for C₉H₁₇NO₉SNa [M + Na]⁺ 338.0516, Found 338.0512.

3.20 Methyl N-[(β-D-glucosyl)sulfonyl]-L-valinate (**3c**)

The title compound **3c** was obtained from the per-acetylated derivative **3b** following the general procedure 3. Lyophilization afforded the title compound **3c** as an off-white solid (93%): mp 89-93 °C; $[\alpha]_D^{25}$ -31 (*c* 1.0, MeOH); R_f 0.49 (95:5 CH₃CN/H₂O); ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.52 (br s, 1H, NH), 5.14, 5.02 (2 x br s, 3H, OH-2, OH-3, OH-4), 4.37 (br s, 1H, OH-6), 4.14 (d, 1H, *J* 9.5 Hz, H-1), 3.87 (d, 1H, *J* 6.0 Hz, NHCH), 3.65 (s, 3H, OCH₃), 3.59 (dd, 1H, *J* 2.5, 11.5 Hz, H-6a), 3.47 (m, 1H, H-6b), 3.42 (t, 1H, *J* 9.0 Hz, H-2), 3.21 (t, 1H, *J* 8.5 Hz, H-3), 3.14 (m, 2H, H-4, H-5), 1.98 (m, 1H, CH₃CHCH₃), 0.89 (d, 1H, *J* 6.5 Hz, CH₃CHCH₃), 0.87 (d, 1H, *J* 6.5 Hz, CH₃CHCH₃); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.0 (CO₂CH₃), 90.5 (C-1), 80.9 (C-5), 77.3 (C-3), 70.4 (C-4), 69.1 (C-2), 61.5 (C-6), 60.5 (NHCH), 51.6 (OCH₃), 30.8 (CH₃CHCH₃), 18.8, 18.0 (CH₃CHCH₃); LRMS (ESI⁺): *m/z* 380 [M + Na]⁺, 396 [M + K]⁺; HRMS: Calcd for C₁₂H₂₃NO₉SNa [M + Na]⁺ 380.0986, Found 380.0970.

3.21 Methyl N-[(β-D-glucosyl)sulfonyl]-R,S-phenylglycinate (**4c'**)

The title compound **4c'** was obtained from the per-acetylated derivative **4b** following the general procedure 3. Lyophilization afforded the title compound **4c'** as a hygroscopic white solid (99%): $[\alpha]_D^{25}$ -24 (*c* 1.0, MeOH); R_f 0.41 (95:5 CH₃CN/H₂O); ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.22 (br s, 1H, NH_R, NH_S), 7.43-7.33 (m, 5H, H_{arom.}), 5.24, 5.22 (2 x br s, 1H, NHCH_R, NHCH_S), 5.16 (br s, 0.6H, OH-3_R), 5.10 (br s, 0.4H, OH-3_S), 5.07 (d, 0.4H, *J* 5.5 Hz, OH-2_S), 5.03 (d, 0.6H, *J* 5.5 Hz, OH-4_R), 4.98 (d, 0.4H, *J* 6.5 Hz, OH-4_S), 4.97 (d, 0.6H, *J* 6.5 Hz, OH-2_R), 4.46 (d, 0.6H, *J* 5.5 Hz, OH-6_R), 4.44 (d, 0.4H, *J* 6.5 Hz, OH-6_S), 4.20 (d, 0.6H, *J* 9.5 Hz, H-1_R), 3.81 (d, 0.4H,

J 9.0 Hz, H-1_S), 3.64 (s, 3H, OCH₃), 3.61 (dd, 0.6H, *J* 12.0, 6.0 Hz, H-6a_R), 3.54 (m, 0.4H, H-6a_S), 3.51 (td, 0.6H, *J* 8.0, 5.0 Hz, H-2_R), 3.42 (m, 1H, H-6b_R, H-6b_S), 3.35 (td, 0.4H, *J* 8.5, 5.0 Hz, H-2_S), 3.23 (br t, 0.6H, *J* 8.5 Hz, H-3_R), 3.19 (m, 0.6H, H-5_R), 3.09 (m, 0.4H, H-3_S), 3.06 (m, 0.6H, H-4_R), 3.01 (td, 0.4H, *J* 9.0, 4.0 Hz, H-4_S), 2.90 (m, 0.4H, H-5_S); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 171.0, 170.6 (CO₂CH₃), 136.8, 128.6, 128.1, 127.6, 127.4 (5 $\times$ C_{arom.}), 91.2 (C-1_R), 90.4 (C-1_S), 81.2 (C-5_R), 80.8 (C-5_S), 77.2 (C-3_R), 77.2 (C-3_S), 70.2 (C-2_R), 70.2 (C-2_S), 69.2, 69.1 (C-4_R, C-4_S), 60.7, 60.5 (C-6_R, C-6_S), 59.6 (NHCH_R), 59.6 (NHCH_S), 52.4, 52.3 (OCH_{3R}, OCH_{3S}); LRMS (ESI⁺): *m/z* 414 [M + Na]⁺; LRMS (ESI⁻): *m/z* = 390 [M - H]⁻.

3.22 Methyl *N*-[(β -D-glucosyl)sulfonyl]-*R*-phenylglycinate (**4c**)

The title compound **4c** was obtained from compound **4b** according to the general procedure 4. Purification by flash chromatography (85:15 CH₂Cl₂/MeOH) afforded the title compound **4c** as a hygroscopic white solid (23%): *R_f* 0.16 (85:15 CH₂Cl₂/MeOH); ¹H NMR (500 MHz, DMSO-*d*₆): δ 8.20 (br s, 1H, NH), 7.42-7.32 (m, 5H, H_{arom.}), 5.23 (br s, 1H, NHCH), 5.15 (br s, 1H, OH-3), 5.02 (d, 1H, *J* 5.5 Hz, OH-4), 4.98 (br s, 1H, OH-2), 4.46 (d, 1H, *J* 5.5 Hz, OH-6), 4.18 (d, 1H, *J* 9.0 Hz, H-1), 3.63 (s, 3H, OCH₃), 3.61 (dd, 1H, *J* 12.0, 6.0 Hz, H-6a), 3.50 (t, 1H, *J* 9.5 Hz, H-2), 3.42 (m, 1H, H-6b), 3.23 (br t, 1H, *J* 8.5 Hz, H-3), 3.18 (m, 1H, H-5), 3.07 (td, 1H, *J* 9.5, 4.0 Hz, H-4); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 170.9 (CO₂CH₃), 129.0, 128.5, 128.5, 128.1, 127.4 (5 $\times$ C_{arom.}), 91.1 (C-1), 81.1 (C-5), 77.1 (C-3), 70.2 (C-2), 69.1 (C-4), 60.6 (C-6), 59.6 (NHCH), 52.3 (OCH₃); LRMS (ESI⁺): *m/z* 414 [M + Na]⁺; HRMS: Calcd for C₁₅H₂₁NO₉SNa [M + Na]⁺ 414.0829, Found 414.0829.

3.23 Methyl *N*-[(β -D-glucosyl)sulfonyl]-L,D-serinate (**5c'**)

The title compound **5c'** was obtained from the per-acetylated derivative **5b** following the general procedure 3. Lyophilization afforded the title compound **5c'** as a hygroscopic slightly yellow solid (99%): [α]_D²⁵ -27 (*c* 1.0, MeOH); *R_f* 0.21 (95:5 CH₃CN/H₂O); ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.49 (d, 0.2H, *J* 8.5 Hz, NH_D), 7.40 (d, 0.8H, *J* 8.5 Hz, NH_L), 5.03 (br m, 3.2H, OH), 4.52 (br m, 0.8H, OH), 4.23 (d, 0.8H, *J* 9.5 Hz, H-1_L), 4.14 (d, 0.2H, *J* 9.5 Hz, H-1_D), 4.08 (m, 1H, NHCH), 3.66 (s, 3H, OCH₃), 3.63 (m, 3H, H-6a, CH₂OH), 3.47-3.42 (m, 2H, H-2, H-6b), 3.23 (t, 0.8H, *J* 9.0 Hz, H-3_L), 3.22 (t, 0.2H, *J* 9.0 Hz, H-3_D), 3.21 (m, 1H, H-5_L, H-5_D), 3.08 (t, 0.8H, *J* 9.0 Hz, H-4_L), 3.03 (t, 0.2H, *J* 9.0 Hz, H-4_D); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 171.2

(CO₂CH_{3D}), 171.1 (CO₂CH_{3L}), 90.9 (C-1_D), 90.1 (C-1_L), 81.3 (C-5_D), 81.0 (C-5_L), 77.4 (C-3_L), 77.3 (C-3_D), 70.6 (C-2_L), 70.4 (C-2_D), 69.6 (C-4_D), 69.5 (C-4_L), 62.6 (NHCH_D), 62.5 (NHCH_L), 61.1 (C-6_D), 60.9 (C-6_L), 58.4 (CH₂OH_D), 58.3 (CH₂OH_L), 52.1 (OCH_{3D}), 52.1 (OCH_{3L}); LRMS (ESI⁺): m/z = 368 [M + Na]⁺, 384 [M + K]⁺; LRMS (ESI): m/z = 344 [M - H]⁻.

3.24 Methyl *N*-[(β-D-glucosyl)sulfonyl]-L-serinate (**5c**)

The title compound **5c** was obtained from compound **5b** according to the general procedure 4. Purification by flash chromatography (9:1 CH₂Cl₂/MeOH) afforded the title compound **5c** as a hygroscopic white solid (36%): R_f 0.43 (85:15 CH₂Cl₂/MeOH); ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.40 (d, 1H, *J* 8.0 Hz, NH), 4.23 (d, 1H, *J* 9.5 Hz, H-1), 4.08 (m, 1H, NHCH), 3.66 (s, 3H, OCH₃), 3.63 (m, 3H, H-6a, CH₂OH), 3.47-3.42 (m, 2H, H-2, H-6b), 3.23 (t, 1H, *J* 9.0 Hz, H-3), 3.20 (m, 1H, H-5), 3.08 (t, 1H, *J* 9.0 Hz, H-4); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 171.0 (OCH₃); 90.0 (C-1); 81.0 (C-5); 77.4 (C-3); 70.5 (C-2); 69.4 (C-4); 62.4 (NHCH); 60.8 (C-3); 58.3 (CH₂OH); 52.0 (OCH₃) assignments were confirmed by ¹H-¹³C HSQC; LRMS (ESI⁺): m/z 368 [M + Na]⁺; HRMS: Calcd for C₁₀H₁₉NO₁₀SNa [M + Na]⁺ 368.0622, Found 368.0606.

3.25 Methyl *N*-[(β-D-glucosyl)sulfonyl]-L-prolinate (**6c**)

The title compound **6c** was obtained from the per-acetylated derivative **6b** following the general procedure 3. Lyophilization afforded the title compound **6c** as a hygroscopic slightly yellow solid (88%): [α]_D²⁵ -87 (*c* 1.0, MeOH); R_f 0.41 (95:5 CH₃CN/H₂O); ¹H NMR (500 MHz, DMSO-*d*₆): δ 5.27 (d, 1H, *J* 6.0 Hz, OH-2), 5.11 (d, 1H, *J* 5.0 Hz, OH-3), 5.03 (d, 1H, *J* 5.5 Hz, OH-4), 4.55 (d, 1H, *J* 9.5 Hz, H-1), 4.54 (t, 1H, *J* 5.5 Hz, OH-6), 4.42 (dd, 1H, *J* 8.5, 3.5 Hz, α -CH), 3.71 (dd, 1H, *J* 10.0, 4.5 Hz, H-6a), 3.65 (s, 3H, OCH₃), 3.46-3.41 (m, 2H, H-2, H-6b), 3.37 (m, 1H, H-5), 3.29 (m, 2H, δ -CH₂), 3.23 (td, 1H, *J* 8.5, 5.0 Hz, H-3), 3.07 (td, 1H, *J* 9.0, 5.5 Hz, H-4), 2.29 (m, 1H, β -CHH), 1.96 (m, 1H, β -CHH), 1.89-1.78 (m, 2H, γ -CH₂); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.8 (CO₂CH₃), 89.4 (C-1), 81.2 (C-5), 77.6 (C-3), 70.4 (C-4), 69.3 (C-2), 60.8 (C-6), 59.5 (α -CH), 51.9 (OCH₃), 49.6 (δ -CH₂), 30.8 (β -CH₂), 24.1 (γ -CH₂); LRMS (ESI⁺): m/z 378 [M + Na]⁺; LRMS (ESI): m/z 390 [M + Cl]⁻; HRMS: Calcd for C₁₂H₂₁NO₉SNa [M + Na]⁺ 378.0829, Found 378.0840.

3.26 Methyl *N,N*-[di-[(β-D-glucosyl)sulfonyl]]-L-lysinate (**7c**)

The title compound **7c** was obtained from the per-acetylated derivative **7b** following the general procedure 3. Lyophilization afforded the title compound **7c** as a hygroscopic orange solid (90%): $[\alpha]_D^{25}$ -22 (*c* 1.0, MeOH); R_f 0.23 (85:15 CH₃CN/H₂O); ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.60 (d, 1H, *J* 8.0 Hz, α -NH), 6.87 (t, 1H, *J* 6.0 Hz, ϵ -NH), 5.14, 5.11 (2 x d, 2H, *J* 5.0 Hz, OH-3, OH-3'), 5.10, 5.05 (2 x d, 2H, *J* 5.0 Hz, OH-2, OH-2'), 5.04 (m, 2H, OH-4, OH-4'), 4.48, 4.45 (2 x t, 2H, *J* 6.5 Hz, OH-6, OH-6'), 4.18 (2 x d, 2H, *J* 9.0 Hz, H-1, H-1'), 3.99 (q, 1H, *J* 7.0 Hz, α -CH), 3.69, 3.63 (2 x dd, 2H, *J* 7.0, 12.0 Hz, H-6a, H-6a'), 3.66 (s, 3H, OCH₃), 3.46-3.41 (m, 4H, H-2, H-2', H-6b, H-6b'), 3.27-3.20 (m, H-3, H-3', H-5, H-5'), 3.10-3.05 (m, 2H, H-4, H-4'), 2.96 (m, 2H, ϵ -CH₂), 1.61 (m, 2H, β -CH₂), 1.43 (m, 2H, δ -CH₂), 1.32 (m, 2H, γ -CH₂); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 172.5 (CO₂CH₃), 90.1, 88.9 (2 x C-1), 81.0, 80.9 (2 x C-5), 77.5, 77.3 (2 x C-3), 70.5 (2C) (2 x C-2), 69.7, 69.4 (2 x C-4), 61.2, 60.8 (2 x C-6), 55.9 (α -CH), 51.9 (OCH₃), 43.0 (ϵ -CH₂), 32.0 (β -CH₂), 29.5 (δ -CH₂), 22.1 (γ -CH₂); LRMS (ESI⁺): *m/z* 635 [M + Na]⁺; HRMS: Calcd for C₁₉H₃₆N₂O₁₆SNa [M + Na]⁺ 635.1398, Found 635.1406.

3.27 N-[(β -D-Glucosyl)sulfonyl]-glycine (**2d**)

Per-acetylated glycoconjugate **2b** (38.3 mg, 0.08 mmol) was added to a solution of a sodium hydroxide in MeOH (0.5 M, 4 mL). The reaction was stirred for 1 h at rt then neutralized with Amberlite IR120-H⁺ resin, filtered and the solvent removed. The remaining residue was dissolved in water and lyophilized. The title compound **2d** (23.7 mg) was obtained as a hygroscopic slightly yellow solid in quantitative yield: $[\alpha]_D^{25}$ -15 (*c* 1.0, MeOH); ¹H NMR (500 MHz, DMSO-*d*₆): δ 4.23 (d, 1H, *J* 9.5 Hz, H-1), 3.67 (d, 2H, *J* 8.0 Hz, NHCH₂), 3.65 (m, 1H, H-6a), 3.43 (dd, 1H, *J* 6.0, 12.0 Hz, H-6b), 3.42 (t, 1H, *J* 9.0 Hz, H-2), 3.22 (br t, 2H, *J* 9.0 Hz, H-3, H-5), 3.06 (t, 1H, *J* 9.0 Hz, H-4); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 171.3 (CO₂CH₃), 90.2 (C-1), 81.4 (C-5), 77.6 (C-3), 70.7 (C-4), 69.7 (C-2), 61.2 (C-6), 44.9 (NHCH₂); LRMS (ESI⁺): *m/z* 324 [M + Na]⁺; HRMS: Calcd for C₈H₁₅NO₉SNa [M + Na]⁺ 324.0360, Found 324.0363.

4. Conclusions

In summary, we have developed a practical and novel strategy for the conjugation of a glycan moiety to the α -amino group of amino acids and to the ϵ -amino group of lysine. This method provides sulfonamide-linked glycoconjugates from readily available starting materials, the reactions are facile and stereoselective, while the sulfonamide link is stable to both acidic and

basic reaction conditions. These attributes, together with the already wide use of the sulfonamide group in medicinal chemistry may see considerable utility of these building blocks for the incorporation of sugars into peptides or proteins, pre- or post- peptide synthesis, potentially leading to a powerful additional synthetic tool for chemical biology.

Supplementary Data

¹H NMR and ¹³C NMR spectra for compounds **2b-9b**, **2c-7c**, **4c'**, **5c'**, **2d**.

Acknowledgements

The Australian Research Council is gratefully acknowledged for financial support (Grant No. DP110100071 to S.-A.P.).

References

1. Gamblin, D. P.; Scanlan, E. M.; Davis, B. G. *Chem. Rev.* **2009**, *109*, 131-163.
2. Ernst, B.; Magnani, J. *Nat. Rev. Drug Discov.* **2009**, *8*, 661-677.
3. Dove, A. *Nat. Biotechnol.* **2001**, *19*, 913-917.
4. Lopez, M.; Drillaud, N.; Bornaghi, L. F.; Poulsen, S.-A. *J. Org. Chem.* **2009**, *74*, 2811-2816.
5. Lopez, M.; Bornaghi, L. F.; Innocenti, A.; Vullo, D.; Charman, S. A.; Supuran, C. T.; Poulsen, S.-A. *J. Med. Chem.* **2010**, *53*, 2913-2926.
6. Czifrák, K.; Somsák, L. *Carbohydr. Res.* **2009**, *344*, 269-277.
7. Zemplén, G. *Ber. Deutsch. Chem. Ges.* **1926**, *59*, 1254-1266.
8. Staněk, J.; Černá, J. *Tetrahedron Lett.* **1963**, *4*, 35-37.
9. Davis, B. G. *Chem. Rev.* **2002**, 579–601.
10. Hotha, S.; Kashyap, S. *J. Org. Chem.* **2005**, *71*, 364-367.
11. Lee, D. J.; Mandal, K.; Harris, P. W. R.; Brimble, M. A.; Kent, S. B. H. *Org. Lett.* **2009**, *11*, 5270-5273.
12. Hang, H. C.; Bertozzi, C. R. *Acc. Chem. Res.* **2001**, *34*, 727-736.
13. Moree, W. J.; van der Marel, G. A.; Liskamp, R. J. *J. Org. Chem.* **1995**, *60*, 5157-5169.
14. Ibatullin, F. M.; Shabalin, K. A.; Jänis, J. V.; Shavvac, A. G. *Tetrahedron Lett.* **2003**, *44*, 7961-7964.